Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Helicos BioSciences has announced a research collaboration with City of Hope focused on cancer molecular diagnostics. City of Hope will use Helicos's proprietary True Single Molecule Sequencing technology for the examination of known cancer-associated gene variants and the potential discovery of new mutations within those genes.
Subscribe to our email newsletter
Helicos’s proprietary True Single Molecule Sequencing (tSMS) technology directly sequences single molecules of DNA or RNA, an advance that enables unparalleled accuracy, simplicity and scale in genomic experimentation.
With the ability to analyze billions of single molecules simultaneously, tSMS technology can directly measure the large sample numbers required to assess the frequency of gene variants within a population of individuals or within a tumor.
Steve Sommer, director of the Department of Molecular Genetics and director of the Department of Molecular Diagnosis at City of Hope, said: “We expect that Helicos’s tSMS technology will allow for coverage that has the power to see beneath the surface and into the depths of the genome.”